What is HC Wainwright’s Estimate for VTYX Q2 Earnings?

Ventyx Biosciences, Inc. (NASDAQ:VTYX) – Research analysts at HC Wainwright issued their Q2 2026 earnings estimates for Ventyx Biosciences in a report issued on Wednesday, November 5th. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($0.56) for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Ventyx Biosciences’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Ventyx Biosciences’ Q3 2026 earnings at ($0.61) EPS, Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($2.35) EPS, FY2027 earnings at ($2.24) EPS, FY2028 earnings at ($1.99) EPS and FY2029 earnings at ($1.57) EPS.

Ventyx Biosciences (NASDAQ:VTYX) last announced its earnings results on Thursday, November 6th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.13.

Several other equities research analysts have also recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Ventyx Biosciences in a research report on Wednesday, October 8th. Wall Street Zen raised Ventyx Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Finally, Oppenheimer increased their target price on shares of Ventyx Biosciences from $9.00 to $14.00 and gave the stock an “outperform” rating in a report on Monday, October 27th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $16.00.

Ventyx Biosciences Price Performance

Shares of NASDAQ:VTYX traded down $1.03 during midday trading on Friday, reaching $8.23. The company’s stock had a trading volume of 761,782 shares, compared to its average volume of 2,124,263. The business’s fifty day simple moving average is $4.08 and its 200-day simple moving average is $2.85. The company has a market capitalization of $587.10 million, a P/E ratio of -4.94 and a beta of 1.23. Ventyx Biosciences has a fifty-two week low of $0.78 and a fifty-two week high of $9.50.

Hedge Funds Weigh In On Ventyx Biosciences

Large investors have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC bought a new position in Ventyx Biosciences in the first quarter valued at approximately $28,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Ventyx Biosciences in the 2nd quarter valued at approximately $71,000. Nuveen LLC bought a new position in shares of Ventyx Biosciences in the first quarter valued at $194,000. Ieq Capital LLC bought a new position in shares of Ventyx Biosciences in the first quarter valued at $223,000. Finally, Pallas Capital Advisors LLC acquired a new position in Ventyx Biosciences during the second quarter worth $38,000. 97.88% of the stock is currently owned by institutional investors and hedge funds.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.